Skip to main content

Research Repository

Advanced Search

All Outputs (1)

CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML (2018)
Journal Article
Anderson, E., Mehta, P., Heywood, J., Rees, B., Bone, H., Robinson, G., …Mayer, L. (2018). CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML. Leukemia Research, 74, 121-129. https://doi.org/10.1016/j.leukres.2018.08.007

© 2018 Elsevier Ltd CPX-351, a liposomal formulation co-encapsulating cytarabine and daunorubicin (DNR) in a synergistic 5:1 M ratio, has shown favourable response in newly diagnosed elderly high-risk AML. This study assessed intracellular ara-CTP le... Read More about CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML.